BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
We have performed the first-ever Budget Impact Analysis (BIA) in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of stem cells isn't sho...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
IRBIS LLC,
2015-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|